Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
Pipt
PiPT is a psychedelic drug of the tryptamine family, structurally related to other dialkyl tryptamines such as DPT and DiPT. It reportedly produces hallucinogenic effects resembling those of related dialkyl tryptamine derivatives, though it is described as relatively weak and short-lasting. Alexander Shulgin listed it as unevaluated in TiHKAL in 1997. It has since been sold as a designer drug, first identified in British Columbia, Canada in 2021. Little is documented about its effects or safety profile.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
PiPT is a psychedelic tryptamine reported to produce effects resembling those of related dialkyl tryptamines, though it is described as relatively weak and short-lasting. The experience is characterized by euphoria, empathy, and insight alongside altered perception and a softening of the sense of self. Both mental and physical stimulation are reported, and little is documented about its effects or safety profile overall.
Physical
Physical effects include stimulation and restlessness alongside decreased appetite, pupil dilation, sweating and chills, muscle tension, and insomnia.
Autonomic
Uncomfortable
Cognitive
The headspace is described in terms of euphoria, empathy, and insight, with a general change in perception and ego softening; confusion is also reported.
Visual
Hallucinatory States
Tactile
Pharmacology
Pharmacodynamics
PiPT is a psychedelic tryptamine reported to produce hallucinogenic effects resembling those of other dialkyl tryptamine derivatives, although it is described as relatively weak and short-lasting. No receptor binding or functional target data for PiPT is available.
Pharmacokinetics
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Harm Potential
History & Culture
PiPT was noted by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), where it was listed as not yet having been evaluated. The compound later appeared as a designer drug, first being identified in 2021 in British Columbia, Canada.
Legality
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Pipt article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.